Please assess the completion status of the following clinical trial:

Trial Title: Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase I portion:~* Relapsed or refractory acute myelogenous or lymphoid leukemia.~* Chronic myelogenous leukemia in accelerated phase or blast-crisis.~* Recurrent or refractory malignant lymphoma or Hodgkin's disease~* Recurrent or refractory multiple myeloma.~* Chronic lymphocytic leukemia, relapsed or with poor prognostic features.~* Myeloproliferative disorder (polycythemia vera, myelofibrosis) with transformation~* Myelodysplastic syndromes with more than 5% blasts.~Phase II portion:~* AML with active disease or beyond CR2.~* MDS with more than 5% blasts.~Exclusion Criteria:~* Clinical progression. Such patients may be treated on other treatment protocols or at the investigator's discretion. Such patients will continue to be monitored for survival and, may be asked to continue to provide specimens for studies of minimal residual disease and immune reconstitution as other treatments are recommended.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Busulfan and fludarabine (Type: EXPERIMENTAL): Intravenous busulfan (Busulfan®) in combination with fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).